首页> 美国卫生研究院文献>Case Reports in Hematology >Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review
【2h】

Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review

机译:浆母细胞性淋巴瘤:晚期人类免疫缺陷患者延长生存期的病例报告和文献复习

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Clinical Practice Points. Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a human immunodeficiency virus-infected patient surviving over 12 years following treatment for advanced PBL with EPOCH chemotherapy and intrathecal therapy. This case highlights the potential for improved survival in PBL with intensive chemotherapy. Further, literature review suggests promising prospects utilizing novel targeted therapies to increase the rate of prolonged responses.
机译:临床实践要点。浆母细胞性淋巴瘤(PBL)是弥漫性大B细胞淋巴瘤的一种罕见且高度侵袭性的变体,在以前的报道中,晚期患者的中位生存期在6到15个月之间。我们在这里报告了人类免疫缺陷病毒感染的患者,在接受EPOCH化疗和鞘内治疗的晚期PBL治疗后存活了12年。该病例强调了通过强化化疗可提高PBL生存率的潜力。此外,文献综述表明,利用新颖的靶向疗法来增加延长的反应率的前景广阔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号